Patent · US Active

Rationally designed antibodies

US9409964B2 · kind B2 · utility

0Cited by

35References

13Claims

0Family size

Assignee

Alexion Pharmaceuticals, Inc. · US

Inventors

Katherine S. Bowdish · Del Mar, US
Shana Frederickson · Solana Beach, US
Mark Renshaw · San Diego, US

Key dates

Filing date	Apr 29, 2014
Grant date	Aug 9, 2016
Priority date	—
Expiry date	Apr 29, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/11
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.